Top 10 Oncology Capital Raises and Investors in the U.S. – April 1st – May 31st, 2026
Several interesting transactions closed in the Oncology sector over the past months. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Hoth Therapeutics, develops and commercialize infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems, received $2 million of development capital through a private placement.
- Shuttle Pharmaceuticals Holdings, clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers, received $9.57 million of development capital through a private placement.
Merger/Acquisition
-
- ACEA Therapeutics, oncology drugs for the treatment of cancer and autoimmune diseases, was acquired by Phoenix Asia Holdings.
- Arcellx, clinical-stage biotechnology company that reimagines cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases, was acquired by Gilead for $6.062 billion.
Later Stage VC
-
- Artax Biopharma, small-molecule drugs that treats autoimmune and inflammatory diseases, raised $19 million of venture funding in the form of convertible debt from Eli Lilly, Advent Life Sciences and Columbus Venture Partners.
- Bamf Health, theranostics platform that diagnoses and treats various diseases, raised $59.65 million of venture funding.
Early Stage VC
-
- Deck Bio, cell receptor therapeutics that targets highly expressed cancer specific peptide MHCs, to develop a single drug to increase response rates and reduce drug resistance for cancer patients, raised $2.6 million of venture funding from Impact Ventures and other investors.
- Lighthouse Pharma, precision medicine that targets Alzheimer’s and other diseases with unmet medical needs, raised $15.21 million of Series A venture funding in a deal led by Double Point Ventures.
Seed
-
- Nok Therapeutics, cell-based immunotherapies that treats cancer by restoring immune defense, raised $1.40 million of seed funding.
- StokedBio, drug discovery platform that creates novel therapeutics for infections and cancer, raised $2.5 million of seed funding.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
